LenioBio
World's most powerful platform aiding CFPS researchers express difficult-to-express proteins \u0026 get up to 30x more protein per euro spent. Learn more here.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
N/A | Early VC | ||
| Total Funding | 000k | ||
| EUR | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 99 % | 19 % | 31 % | 2 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (1604 %) | (1241 %) | (1939 %) | (2516 %) | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Dealroom estimates
Related Content
LenioBio GmbH is a biotechnology startup based in Düsseldorf, Germany, specializing in protein expression technology. The company has developed a proprietary platform called ALiCE, which stands for "Active Lysate for In vitro Expression." This platform is designed to produce complex proteins that are typically difficult to express using traditional methods. ALiCE leverages intact organelles, such as active mitochondria and reformed endoplasmic reticulum, to provide a continuous energy supply and enable the proper folding and glycosylation (a process where sugars are added to proteins) of complex proteins. This results in significantly higher yields of protein production compared to other cell-free systems.
LenioBio serves a diverse range of clients, including pharmaceutical companies, academic research institutions, and biotech firms. These clients require high-quality proteins for various applications, such as drug development, diagnostics, and research. The market LenioBio operates in is the global biotechnology and life sciences sector, which is continually growing due to advancements in medical research and the increasing demand for innovative therapeutic solutions.
The business model of LenioBio revolves around selling its ALiCE protein expression kits and providing custom protein production services. The company generates revenue by offering these products and services to its clients, who benefit from the high efficiency and scalability of the ALiCE platform. Additionally, LenioBio has secured funding through grants, such as the prestigious Horizon 2020 SME 2 Grant, which supports the acceleration and scaling up of its technology.
In summary, LenioBio is a pioneering biotech company that simplifies the production of complex proteins, serving a wide range of clients in the life sciences industry. Its innovative ALiCE platform offers a scalable and efficient solution for protein expression, positioning the company for continued growth and success.
Keywords: Biotechnology, Protein Expression, ALiCE Platform, Complex Proteins, Life Sciences, Pharmaceutical, Research, Custom Services, High Yield, Innovation.